• Explore /
  • Poster
  • / Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.

Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.

Abstract Poster

Authors

null

Akhila Ganeshi Wimalasingham

Barts Health NHS Trust, London, United Kingdom

Akhila Ganeshi Wimalasingham , Melissa Mary Phillips , Louise Lim , Sukaina Rashid , Peter Edward Hall , Ramsay Khadeir , Jeremy P. C. Steele , John Conibear , Xiaoxing Feng , Stephen Ellis , Pui Ying Chan , Jim Thomson , Amanda L. Johnston , John S. Bomalaski , Simon Pacey , Michael Sheaff , Peter Wojciech Szlosarek

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02029690

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9097)

DOI

10.1200/JCO.2019.37.15_suppl.9097

Abstract #

9097

Poster Bd #

420

Abstract Disclosures

Similar Posters

First Author: Melissa Phillips

Poster

2018 ASCO Annual Meeting

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

First Author: Nathaniel R. Evans

First Author: Pui Ying Chan

First Author: Fatemeh Ardeshir-Larijani